Hillhouse, Quan Capital Lead $93M Series B Round In Biopharma Firm NextCure

Chinese investment firms Hillhouse Capital and Quan Capital have invested US$93 million in a series B equity financing round in bio-pharmaceutical company NextCure Inc., which mainly focuses on developing immunomedicines for cancers and other diseases, according to an announcement released by NextCure.

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Register Now

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!

Already have an account or paid subscription? Log in

Caishen.Co - Primary Data for China Secondary Investment and Stock Markets